Side-by-side · Research reference

CrystagenvsMOTS-c

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-StrongHUMAN-REVIEWED16/68 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

01Mechanism of Action

Parameter

Crystagen

MOTS-c

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

MOTS-c

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

Evidence basis

Animal / mechanistic

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Duration

Unknown — chronic administration presumed in animal models

4–12 weeks (experimental)

Optimal cycle length unknown.

Half-life

Not reported

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

Lower / starter dose

—

2.5–5 mg / week

Recommended due to limited human data.

Reconstitution

—

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Timing

—

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

03Metabolic / Fat Loss Evidence

Parameter

Crystagen

MOTS-c

Primary fat target

—

Diet-induced / metabolic obesity; systemic fat utilization

Quantified reduction

—

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

IGF-1 impact

—

No direct IGF-1 pathway; AMPK-mediated

Effect on lean mass

—

High dose significantly ↑ lean mass in mice

Insulin sensitivity

—

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

Triglycerides

—

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

Glucose metabolism

—

Improved glucose tolerance; GLUT4 upregulationLee 2015

Effect reversibility

—

Unknown — no long-term follow-up data

Context dependency

—

No effect in normal-chow mice; requires metabolic stressReynolds 2021

Key publication

—

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

04Side Effects & Safety

Parameter

Crystagen

MOTS-c

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Injection site reaction

—

Mild irritation (reported)

Fluid retention / Edema

—

Not reported

Glucose intolerance

—

Improves glucose toleranceLee 2015

Cardiovascular

—

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

Cancer risk

—

Contradictory data — some models suggest pro-proliferative effects

CNS / Neurological

—

Insomnia, headache (anecdotal reports)

GI symptoms

—

Nausea, stomach discomfort (reported)

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid — insufficient safety data

Evidence quality

—

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

05Administration Protocol

Parameter

Crystagen

MOTS-c

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

5. Needle

—

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction